These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 18393983)
1. Health status in Iranian haemophilic patients. Karimi M; Rahmani S; Ardeshiri R; Pasalar M Haemophilia; 2008 May; 14(3):615-7. PubMed ID: 18393983 [No Abstract] [Full Text] [Related]
2. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors. Ullman M; Hoots WK Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398 [TBL] [Abstract][Full Text] [Related]
3. Million dollar miracles. Smith SD Minn Med; 2006 Apr; 89(4):30-5, 51. PubMed ID: 16681280 [No Abstract] [Full Text] [Related]
4. The economics of immune tolerance and treatment of hemophiliacs with inhibitors. Kessler CM; Aledort LM Vox Sang; 1996; 70 Suppl 1():74-6. PubMed ID: 8869476 [No Abstract] [Full Text] [Related]
5. Prevention of haemophilic synovitis: prophylaxis. Lee CA Haemophilia; 2007 Nov; 13 Suppl 3():20-5. PubMed ID: 17822517 [TBL] [Abstract][Full Text] [Related]
6. Some aspects on the management of hemophilia. Aledort LM Thromb Haemost; 1995 Jul; 74(1):440-3. PubMed ID: 8578502 [No Abstract] [Full Text] [Related]
8. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610 [TBL] [Abstract][Full Text] [Related]
9. In that case. Anderson L; Cunningham N J Bioeth Inq; 2005; 2(2):109. PubMed ID: 16317869 [No Abstract] [Full Text] [Related]
10. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895 [TBL] [Abstract][Full Text] [Related]
13. Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs. Tagliaferri A; Rivolta GF; Rossetti G; Pattacini C; Gandini G; Franchini M Thromb Haemost; 2006 Oct; 96(4):542-3. PubMed ID: 17003937 [No Abstract] [Full Text] [Related]
14. Prophylaxis vs. episodic treatment to prevent joint disease in severe hemophilia. Bernstein MJ N Engl J Med; 2007 Nov; 357(20):2087; author reply 2087-8. PubMed ID: 18003967 [No Abstract] [Full Text] [Related]
15. [Dental care for hemophilic patients. I. General discussion]. Ned Tijdschr Tandheelkd; 1982 Apr; 89(4):143-9. PubMed ID: 6213873 [No Abstract] [Full Text] [Related]
18. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Chen SL Am J Manag Care; 2016 Apr; 22(5 Suppl):s126-33. PubMed ID: 27266809 [TBL] [Abstract][Full Text] [Related]
19. Healthcare costs among patients with hemophilia A treated with factor replacement or bypassing agents. Swindle JP; Xu Y; Mu Y; Solari PG Curr Med Res Opin; 2019 Aug; 35(8):1433-1440. PubMed ID: 30888200 [No Abstract] [Full Text] [Related]
20. Investing in hemophilia care: benefits and costs for patients and society. Scalone L Semin Hematol; 2008 Apr; 45(2 Suppl 1):S31-4. PubMed ID: 18544422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]